Detailed Financial Summary
Mylan previously had two reportable segments, the "Mylan Segment" and the "Matrix Segment." With the acquisition of Merck Generics, Mylan now has three reportable segments: Generics Segment (or "Generics"), Specialty Segment (or "Specialty") and the Matrix Segment (or "Matrix"). The former Mylan Segment is included within the Generics Segment. Additionally, certain general and administrative and research and development expenses not allocated to the segments, as well as litigation settlements and non-operating income and expenses, are reported in Corporate/Other.
Total revenues for the quarter ended December 31, 2007 increased by 188% or $753.6 million to $1.16 billion from $401.8 million in the same prior year period. Approximately $793.5 million represents amounts contributed through acquisitions.
Generics Segment revenues are derived from sales in Europe, the Middle East & Africa (collectively, "EMEA"), North America and Asia Pacific.
Revenues from North America were $416.3 million for the three months ended December 31, 2007 compared to $401.8 million for the same prior year period, representing an increase of $14.5 million or 4%. Revenues of approximately $54.4 million were realized in North America as a result of the acquisition of Merck Generics.
Revenues from EMEA and Asia Pacific, as well as revenues from the
Specialty Segment, were all the result of the acquisition of Merck
Generics. For EMEA, revenues for the quarter ended December 31, 2007 were
|SOURCE Mylan Inc.|
Copyright©2008 PR Newswire.
All rights reserved